Filing Flows › Adaptive Biotechnologies (ADPT) › Q2 2026 › vs Q2 2025
Adaptive Biotechnologies (ADPT) Q2 2026 vs Q2 2025 (year over year)
Adaptive Biotechnologies's revenue rose $12.7M (+22%) from $58.9M in Q2 2025 to $71.6M in Q2 2026.
Adaptive Biotechnologies, Q2 2026: revenue $71.6M (+22% year over year), operating margin -22.0%, net loss $39.9M, operating cash flow −$6.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $71.6M | $58.9M | $12.7M | +22% |
| Net loss | $39.9M | $25.6M | $14.3M | +56% |
| Costs & expenses | $111M | $84.5M | $27.0M | +32% |
| Operating costs | $87.3M | $83.9M | $3.4M | +4% |
| Interest & other, net | $24.2M | $557K | $23.6M | 43× |
| Cost of revenue | $20.2M | $18.0M | $2.2M | +12% |
| Research & development | $19.2M | $24.1M | −$5.0M | -21% |
| Sales & marketing | $26.4M | $23.6M | $2.8M | +12% |
| General & admin | $21.2M | $17.8M | $3.4M | +19% |
| Other operating costs | $423K | $423K | $0 | 0% |
| Operating cash sources | $39.9M | $25.6M | $14.3M | +56% |
| Depreciation & amortization | $3.7M | $4.1M | −$376K | -9% |
| Share-based compensation | $11.1M | $13.4M | −$2.2M | -17% |
| Working capital & other | $18.7M | −$4.3M | $23.0M | — |
| Cash used in operations | $6.4M | $12.4M | −$6.0M | -49% |
| Net loss absorbed | $39.9M | $25.6M | $14.3M | +56% |
Questions
How much did Adaptive Biotechnologies's revenue grow year over year in Q2 2026?
Adaptive Biotechnologies's revenue rose $12.7M (+22%) from $58.9M in Q2 2025 to $71.6M in Q2 2026.